Comstock Inc. (LODE) - Q2 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended June 30, 2026. Comstock Inc. operates through four primary segments: Metals (solar panel recycling), Mining (gold/silver assets, currently held for sale), Fuels (Bioleum subsidiary for renewable fuels), and Strategic Investments. The company is a non-accelerated filer and smaller reporting company.
Key Financial Metrics
| Metric | Q2 2026 (3 Months) | YTD 2026 (6 Months) | YTD 2025 (6 Months) |
|---|---|---|---|
| Revenue | $272,824 | $586,280 | $1,125,361 |
| Net Loss | $(25,468,401) | $(34,851,818) | $(16,920,874) |
| EPS (Basic & Diluted) | $(0.34) | $(0.49) | $(0.63) |
| Cash & Equivalents | $31,405,235 | $31,405,235 | $18,587,742 |
| Working Capital | $39,947,071 | $39,947,071 | N/A |
| Long-Term Debt | $0 | $0 | N/A |
Note: The company reported no outstanding debt as of June 30, 2026. The "Marathon SAFE Note" of $10.9 million is classified as a liability measured at fair value, not traditional debt.
Material Changes vs. Prior Period
- Revenue Decline: YTD revenue decreased by $539,081 (48%) compared to the prior year, primarily due to lower decommissioning services revenue in the Metals segment following a large emergency project in Q1 2025.
- Significant Impairments: The company recorded a $13.6 million impairment of intangible assets and a $1.7 million impairment of property, plant, and equipment, both associated with the Bioleum (Fuels) segment. Management concluded that certain acquired technologies (Flux Photon and Fenix) were no longer relevant to current plans.
- Investment Impairment: A $1.0 million loss was recognized on the impairment of the investment in Magnesis Corporation.
- Asset Sales: The company recognized a $1.4 million gain on the sale of royalty and mineral rights to Mackay Precious Metals Inc.
- Equity Financing: In Q1 2026, the company raised approximately $57.5 million in gross proceeds via a Confidentially Marketed Public Offering (CMPO), significantly boosting cash reserves.
Guidance, Outlook, and Risks
- Mining Divestiture: On June 21, 2026, Comstock entered an agreement to sell its mining assets (Comstock Mining LLC, etc.) to Mackay Precious Metals. The deal includes an initial $20 million cash payment, stock consideration, a $7 million deferred payment, and a potential $10 million contingent payment. Assets are classified as "Held for Sale."
- Metals Segment: The first industry-scale solar panel recycling facility in Nevada is expected to be commissioned in Q3 2026. The company plans to build up to five facilities over the next five years.
- Bioleum Strategy: The Fuels segment is pivoting away from impaired technologies to focus on Hexas Biomass feedstock and commercial demonstration facilities. An equity financing for Bioleum is a key 2026 objective.
- Liquidity: Management believes existing cash ($31.4 million), proceeds from the mining sale, and asset monetization are sufficient to fund operations for the next 12 months.
- Legal Risks:
- Magnesis Litigation: Magnesis Corporation filed a complaint alleging breach of contract regarding license payments. Comstock intends to defend vigorously.
- Bioleum Shareholder Suit: Former Bioleum employees/shareholders filed a complaint alleging fraudulent inducement and breach of fiduciary duty regarding charter amendments.
Investor Verification Checklist
- Mining Sale Closing: Verify the closing date and receipt of the initial $20 million cash payment from the Mackay transaction, which is subject to TSX-V approval.
- Metals Facility Commissioning: Confirm the timeline for the commissioning of the industry-scale solar recycling facility in Q3 2026 and subsequent revenue ramp-up.
- Bioleum Financing: Monitor progress on the planned equity financing for the Bioleum subsidiary to fund commercial demonstration projects.
- Legal Proceedings: Track developments in the Magnesis and Bioleum shareholder lawsuits to assess potential financial exposure.
- Impairment Rationale: Review future disclosures regarding the strategic shift in the Bioleum segment to ensure the $15.3 million in impairments does not signal further asset write-downs.